Invanz Sandbox: Difference between revisions

From Proteopedia
Jump to navigationJump to search
← Older editNewer edit →
No edit summary
No edit summary
Line 10: Line 10:


<scene name='Invanz Sandbox/74/746003/4qu3/1' target='4QU3'>Beta-lactamase Ges-2 Acyl Enzyme Complex</scene>  
<scene name='Invanz Sandbox/74/746003/4qu3/1' target='4QU3'>Beta-lactamase Ges-2 Acyl Enzyme Complex</scene>  
<scene name='Invanz Sandbox/74/746003/3zgp/1' target='3ZGP'>NMR Structure of the Catalytic Domain From E. Faecium L,d- Transpeptidase Acylated by Ertapenem</scene>
   
   
There are various structural features of Invanz that make make administration of the drug easy. Older carbapenems required patients to take a dehydropeptidase-1 (DHP-1) inhibitor since the DHAP enzyme found in the human renal system could interfere with the action of the carbapenem by degrading the antibiotic  <ref name="Invanz1" />. Invanz is a unique antibiotic because it has a 1-beta-methyl substituent that shields the beta-lactam carbonyl from DHP-1 degradation <ref name="hammond">...</ref>. The meta-substituted benzoic acid substituent increases the molecular weight and makes the drug more soluble in nonpolar solvents. Additionally, the carboxylic acid substituent becomes ionized at physiological pH, so the ertapenem has a net negative charge. Increased solubility in non polar solvents and the net negative charge allows the drug to bind human plasma proteins with an extended half-life in the blood stream, and thus the drug only has to be administered once daily <ref name="hammond" />. Invanz largely travels in the bloodstream bound to the human plasma protein albumin <ref name="merck" />.  
There are various structural features of Invanz that make make administration of the drug easy. Older carbapenems required patients to take a dehydropeptidase-1 (DHP-1) inhibitor since the DHAP enzyme found in the human renal system could interfere with the action of the carbapenem by degrading the antibiotic  <ref name="Invanz1" />. Invanz is a unique antibiotic because it has a 1-beta-methyl substituent that shields the beta-lactam carbonyl from DHP-1 degradation <ref name="hammond">...</ref>. The meta-substituted benzoic acid substituent increases the molecular weight and makes the drug more soluble in nonpolar solvents. Additionally, the carboxylic acid substituent becomes ionized at physiological pH, so the ertapenem has a net negative charge. Increased solubility in non polar solvents and the net negative charge allows the drug to bind human plasma proteins with an extended half-life in the blood stream, and thus the drug only has to be administered once daily <ref name="hammond" />. Invanz largely travels in the bloodstream bound to the human plasma protein albumin <ref name="merck" />.  
Retrieved from "https://proteopedia.org/Invanz_Sandbox"